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Abstract
Respiratory syncytial virus (RSV) infection is the most significant cause of viral death in infants
worldwide. The significant morbidity and mortality associated with this disease underscores the
urgent need for the development of an RSV vaccine. The development of an RSV vaccine has
been hampered by our limited understanding of the human host immune system, which plays a
significant role in RSV pathogenesis, susceptibility and vaccine efficacy. As a result, animal
models have been developed to better understand the mechanisms by which RSV causes disease.
Within the past few years, a revolutionary variation on these animal models has emerged – age at
time of initial infection – and early studies in neonatal mice (aged <7 days at time of initial
infection) indicate the validity of this model to understand RSV infection in infants. This article
reviews available information on current murine and emerging neonatal mouse RSV models.
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Respiratory syncytial virus (RSV) is the leading viral respiratory pathogen in infants and
young children worldwide [1]. Most children are infected during their first RSV season; and
by 2 years of age, almost all children have been infected with RSV and over 50% have been
infected twice [2–4]. Few infants are infected prior to 2 months of age and the highest
incidence of infection is seen between 3 and 4 months of age [2]. The global burden of this
disease is estimated at 64 million cases and 160,000 deaths annually [101]. Yearly in the
USA, it is responsible for 85,000 to 144,000 infant hospitalizations [5]. Healthcare costs are
estimated at US$365–585 million per year [6], and the economic impact, in relation to days
lost from work, is greater than that of influenza [7]. Mortality rates from primary infection
are 0.005–0.02% for healthy and 1–3% for hospitalized children [8,9]. Importantly, long-
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term resistance to RSV infection does not develop and reinfection is common and often
causes severe illness among those with chronic lung or heart disease [10,101].
Despite the considerable worldwide impact of RSV infection, a vaccine to protect against
RSV remains elusive. There is also a need for safe and efficacious therapeutics against RSV
infection. Ribavirin is the only approved antiviral therapy for RSV; however, it is rarely
used in the pediatric population owing to its teratogenic potential and its limited
effectiveness [11–13]. Humanized monoclonal antibodies (RespiGam® and Synagis®,
MedImmune, Gaithersburg, MD, USA) are often used to prevent infections in infants and
are currently only recommended for use in high-risk infants and young children.
Unfortunately, these antibodies are only partially effective and are administered to less than
5% of the at-risk children [13]. Development of an effective vaccine and/or therapeutics has
been hampered significantly by our lack of understanding of the virus, the host immune
system at time of initial infection (i.e., infant/neonatal immunity), and the interaction
between the virus and the host immune system.
Studies are not feasible in humans because of safety issues; consequently, several animal
models have been developed to better understand the mechanisms by which RSV causes
disease. The most common include rodents, cows, sheep and nonhuman primates. Each
model has its advantages and disadvantages and the model chosen often depends on the end
points being studied (Table 1). For example, studies focusing on immune mechanisms of
disease are generally performed in mouse models owing to their immunological similarity
with humans. Other reasons include the availability of numerous reagents including
immunochemicals and genetically modified strains, not to mention reduced animal
husbandry and housing costs. Animal models have proven valuable in understanding RSV
pathogenesis; however, the majority of these studies were performed in adult animal models
(Figure 1) and it is unclear how accurately data derived from these models reflect human
disease. In fact, it could be argued that the use of adult animal models is the reason for the
discrepancies between human and animal model data. Current data suggest that a more
relevant model for the human infant is the neonatal mouse. This article will give an
overview of currently used murine RSV models, discuss their relevance to human disease,
and explore the emerging neonatal mouse model.
RSV in humans
In human infants, RSV causes both upper and lower respiratory tract infection with an
incubation time ranging from 2 to 8 days [102]. Clinical symptoms include runny nose,
sneezing, coughing and/or fever. Most infants recover from the infection in 1–2 weeks;
however, 25–40% develop clinically significant disease as evidenced by outpatient visits or
hospitalizations (0.5–2% require hospitalization) [14].
Severe RSV infection in infants induces bronchiolitis, interstitial pneumonitis and
sometimes alveolitis [15]. The peribronchiolar infiltrates include primarily macrophages/
monocytes, lymphocytes, neutrophils and occasionally eosinophils. Interstitial inflammatory
cells are primarily mononuclear cells and occasionally neutrophils. In the alveolar spaces,
macrophages/monocytes are the cells that predominate.
A biased Th2-cell response to RSV has been speculated to be, at least partially, responsible
for RSV pathogenesis in human infants [16]. Although inconsistent cytokine data has been
reported due to different specimen collection methods and sample population diversity, Th2
cytokines including IL-4 and IL-5 have been found significantly elevated in the serum of
RSV-infected infants compared with that of influenza-infected infants [17]. IL-4 is also
detected more often than IFN-γ in the bronchoalveolar lavage fluid of RSV-infected infants
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[18]. Moreover, detection of IL-4 and IL-5 in the blood of infants is associated with more
severe RSV disease, whereas elevated IFN-γ levels are associated with milder disease [19].
Recent data from infants further indicate that, in addition to a Th2-biased immune response,
there is also an insufficient T-cell response, which plays a role in RSV pathogenesis. In fact,
only low numbers of both CD4+ and CD8+ T cells are recruited to lungs of RSV-infected
infants [15,20]. Interestingly, CD3+ cells are recruited to the airway and lung parenchyma
after RSV infection in infants, but a substantial number of them are double-negative cells
[15]. This CD3+CD4−CD8− population remains poorly defined and could represent T-
regulatory cells [21]; natural killer T cells, which have been observed in a mouse model of
RSV [22], or double-negative T cells, which have been observed in lungs of RSV-infected
mice [23,24].
Another important characteristic of severe RSV infection in human infants is that the
infection causes significant airway obstruction due to sloughing of epithelial cells, papillary
projections of the epithelium and macrophage recruitment to the airway lumen [15]. The
sloughed epithelial cells are positive for RSV antigen, indicating infection of these cells by
the virus, whereas the papillary projections are negative for RSV antigen. Following RSV
infection, bronchiolar epithelial cells become caspase-3 positive, suggesting that sloughed
epithelial cells undergo apoptosis [20]. In summary, these observations suggest that RSV
infects epithelial cells and possibly other cells, causes apoptosis of these cells, and
eventually leads to the obstruction of the airway.
Current murine models
A quick search of PubMed reveals that the most common experimental nonprimate model of
RSV infection excluding cows is murine models, including BALB/c mice and cotton rats
(Figure 1).
The adult mouse model
Mouse models of RSV infection and induced disease have been developed and used
extensively to understand mechanisms linking RSV with subsequent wheeze (i.e., asthma).
In general, significant acute pulmonary inflammation and airway hyper-responsiveness are
observed in the majority of mouse models. Following RSV infection, viral load usually
peaks by the fourth day and wanes by the eighth day. Peribronchovascular inflammation is
observed as early as 3 days post-infection (dpi) and reaches a maximum at 6 dpi with a clear
involvement of alveolar space [25]. The infiltrates are composed primarily of lymphocytes
and monocytes/macrophages [25], with a few neutrophils and eosinophils [26]. NK cells are
the first lymphocyte subpopulation to enter the lung during an RSV infection and are
responsible for the high amount of IFN-γ seen early in the infection [27–29]. This is
followed by the recruitment of both CD4+ and CD8+ T cells and the release of type I
cytokines (IL-12 and IFN-γ) with low levels of type II cytokines (IL-4, -5 and -13) [26–29].
CD8+ T cells [30] accompanied by IFN-γ [28] are the main effectors responsible for
facilitating viral clearance, but also induce host tissue damage and pathology.
Human infants vaccinated with formalin-inactivated RSV (FI-RSV) and subsequently
infected with community-acquired RSV developed severe respiratory illness, whereas
nonvaccinated children infected with RSV showed significantly milder symptoms [31].
Clinical symptoms of the vaccine-enhanced illness were typically wheezing, cough and
coryza. Lung histopathology of the children who died revealed severe infiltration of
monocytes and eosinophils [31–33]. Adult mice have been used extensively to understand
FI-RSV-enhanced disease. Similar to humans, FI-RSV-vaccinated mice challenged with
RSV develop extensive pulmonary pathologies and characteristic Th2 responses including
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elevated levels of IL-4, -5 and -13; reduced levels of IL-12; and pulmonary eosinophilia
[34,35]. Also, similar to humans, the mice developed high titers of RSV-specific antibodies
that fail to offer protection from subsequent infection [34,35].
Many of the immunological responses of mice to RSV infection are similar to humans, and
the use of this model system has greatly enhanced our understanding of RSV pathogenesis.
However, there are a few significant differences between mice and men that should be
considered. The most important is that RSV is a human pathogen and replicates poorly in
mice. This requires high inoculums for productive infection and induction of pathology.
Second, viral replication does not appear to occur in the bronchioles of mice as it does in
humans; in fact, RSV primarily infects alveolar pneumocytes in mice [36]. Lung
histopathology induced by RSV in mice differs from that of humans in some aspects,
including reduced neutrophil involvement and lack of airway obstruction [25]. Finally,
clinical illness is monitored by weight loss and ruffled fur instead of runny nose, sneezing,
cough and/or fever.
The cotton rat model
Cotton rats were developed as an RSV model because they are highly susceptible to RSV
and permissive to RSV replication [37]. RSV is detectable in both nasal tissue and lungs of
infected cotton rats at 2 dpi. Pulmonary viral load usually peaks by the fifth day of infection.
Viral load wanes from this point forward and becomes undetectable by 8 dpi [38]. In stark
contrast to mouse models of RSV, viral replication in the rat lung is 50–1000-fold greater
[39].
Respiratory syncytial virus infection in cotton rats induces pulmonary histopathology similar
to that observed in humans, although it does not cause overt clinical symptoms. Infected
animals develop prominent epithelial degeneration of nasal mucosa, discernable
peribronchiolitis, perivasculitis and interstitial pneumonitis [38]. These pathologies are
present as early as 2 dpi peak at 6 dpi, and decline by 8 dpi [38]. In contrast to human data,
the primary cells recruited to the lungs are neutrophils and lymphocytes [40].
In addition to modeling natural RSV infection, cotton rats have also been used extensively to
study vaccine-enhanced disease [41]. Cotton rats vaccinated with FI-RSV develop enhanced
disease upon RSV challenge. The vaccinated cotton rats experience more prominent
pulmonary inflammation as observed in human infants who received FI-RSV as a vaccine
and subsequently acquired RSV. However, there are differences between cotton rat and
human responses to FI-RSV. FI-RSV-vaccinated cotton rats experienced extensive
pulmonary inflammation consisting of neutrophils and lymphocytes, not monocytes and
eosinophils as in humans [31–33]. Human data suggest a Th2-type immune response in the
lung characterized by eosinophilia [31], which is not shown in cotton rat models. In fact, FI-
RSV-vaccinated cotton rats express augmented cytokines of both types, including Th2 (IL-4,
-5 and -9) and Th1 (IFN-γ and IL-12p40) upon challenge [42].
Cotton rats are the pharmaceutical model of choice and are used to study the efficacy of a
variety of antiviral drugs and prophylaxis reagents. The two approved reagents (RespiGam®
and Synagis®, [MedImmune]) for prevention of RSV infection were both tested in the
cotton rat model and progressed to clinical trials without further examination in primate
models [43–46]. Even the dose of the drug being used in human infants was accurately
predicted from the cotton rat model.
We hypothesize that age-dependent differences in immune response to RSV exists in the
cotton rat as they do in humans. In fact, one study reported that neonatal cotton rats (aged 3
days) infected with RSV showed a higher (~tenfold) viral load in the nasal tissue, tracheas
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and lungs compared with viral load in adults [47]. Therefore, we suggest that a more
relevant model of human disease can be obtained through the development of a neonatal
cotton rat RSV-infection model.
In summary, both mice and cotton rats are valuable models to help understand human RSV
infection. Cotton rats are extremely useful in developing pharmaceuticals for RSV therapy
and prophylaxis, as they are highly permissive for RSV infection [47] and the lung
histopathology induced by RSV infection in cotton rats is more similar to human infants.
The major limitation of this model is that the cotton rat fails to develop a Th2-skewed
immune response to RSV as observed in humans. Although mice are less permissive for
RSV replication as compared with cotton rats, the plethora of reagents make them
invaluable in elucidating the mechanisms of RSV pathogenesis. In addition, a Th2-biased
response to RSV reinfection in mice has been independently reported by different
laboratories, including ours [48–50].
Age of initial RSV infection plays a key role in pathogenesis
The immune systems of neonates and adults differ substantially. In neonates, total
lymphocyte and dendritic cell numbers are significantly lower compared with adults [51].
Lymphoid follicles, follicular dendritic cell networks and germinal center structures of
secondary lymphoid tissue, known to be crucial for antibody development, are absent at
birth and form between a few days to a few weeks of age [52]. The complete development
of antigen-presenting cells is achieved several weeks after birth [53].
The age of initial infection is considered to be an important risk factor for RSV-mediated
diseases [14]. Infants are particularly susceptible to RSV infection and rates of infection and
disease severity are highest in those under 6 months of age [54]. Both the increased
susceptibility to RSV infection and disease severity are believed to be partly due to an
immature immune system [55,56]; however, other factors such as airway size and
maturation status of the lung, although not discussed here, may also contribute to the
increased susceptibility and disease severity.
Several retrospective and prospective studies suggest a link between RSV lower respiratory
tract infections and later development of asthma in infants [57–62]. The Tucson Children’s
Respiratory study demonstrates that children with even mild RSV infections are four-times
more likely to have recurrent, frequent wheeze to age 13 years [61]. By contrast, an 18–20
year prospective cohort study from Finland clearly demonstrates that severe bronchiolitis
(RSV was responsible for 71% of viral diagnoses [63]) requiring hospitalization in infancy
is a significant risk factor for asthma that extends into early adulthood and is independent of
atopy [64]. In the Tucson Children’s Respiratory study, increased risk for RSV-associated
wheeze was almost insignificant at age 13; whereas in the Finland study, increased risk for
asthma persisted to age 20 years (end point of the study). The Finnish study is consistent
with a more recent study performed in Sweden in which history of hospitalization for RSV
bronchiolitis was the significant risk factor identified at 18 years of age for current asthma
[65]. A more recent study, The Tennessee Children’s Respiratory Initiative, using a cohort
of more than 95,000 infants also further demonstrates a role for severe respiratory viral
infection in the development of asthma [14]. The reasons for the discrepancy between the
studies are unclear but may have to do with the cohorts used in the studies. The birth cohort
in the Tucson study consisted of infants and young children, birth to 3 years of age, with
mild wheezing, which in most cases did not require hospitalization. The birth cohort in the
Finland and Sweden study consisted of infants (<24 months and <12 months, respectively,
with 91% younger than 6 months of age at time of hospital admission) with severe
bronchiolitis requiring hospitalization [61,64,65]. In total, these studies establish that age at
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initial infection and severity of RSV-induced bronchiolitis is a strong predictor of asthma
susceptibility. To answer the question of whether severe RSV infection predisposes to
asthma, age-relevant mouse models are being used.
A mouse model of neonatal RSV infection, which recapitulates many of the pathologies
associated with RSV infection in infants, has recently been developed. In this model, mice
infected as neonates (aged ≤7days) develop long-term ‘asthma’ characterized by increased
airway hypersensitivity, mucus hyperproduction, Th2 cytokine and cellular responses and
airway remodeling [48,49,66,67]. Data from these mouse models closely resemble the data
from human epidemiological studies (i.e., that the age of initial infection is the major
determinant in the persistence of lung dysfunction into early adulthood). In mice, when
primary RSV infection occurs in the first week of life, a subsequent RSV infection or
allergen challenge causes severe lung immuno- and patho-physiology similar to asthma
[48,49,67]. However, when primary RSV infection occurs in weanlings or adults, overt
pulmonary pathophysiology does not persist and is significantly less severe following
secondary RSV infection [49] or allergen challenge [66]. The emerging data suggest that
disease outcome of RSV infection even in the mouse is dictated by the age at initial
infection. This further suggests that an inchoate immunological response may be responsible
for disease outcome and therefore highlights the importance of the neonatal mouse model
for a disease that affects human infants.
Expert commentary & five-year view
Although intensive research efforts have been made to understand the pathogenesis of RSV
infection, many questions remain unanswered. Although RSV has been prioritized for
control and vaccine development by national and global health organizations for more than
50 years, no effective vaccine or therapy exists.
Progress in RSV vaccine development has been very slow owing to the detrimental effects
of the FI-RSV vaccine. The failure of the FI-RSV vaccine was primarily a consequence of
our limited understanding of the pathophysiology of RSV infection and most importantly
due to our lack of knowledge of the infant immune system. Even today the importance given
towards the understanding of the pathogenesis of RSV infection in an age-relevant model is
minimal, with the majority of RSV studies being conducted in adult animal models.
Attaining more knowledge of neonatal/infant immune responses is essential if we are to
develop effective vaccines not only for RSV but for other pediatric diseases.
As soluble mediators of the immune system, Th2 cytokines may play a key role in infantile/
neonatal RSV pathogenesis (Figure 2). IL-4 and IL-13 are classical Th2 cytokines that have
been known to be central mediators in RSV-mediated airway disease in both mouse models
[68] and humans [69,70]. Similarly, the receptors of IL-4 and IL-13 have also been shown to
be key players in RSV pathogenesis [16,69–71]. IL-4 has two receptors, the type I and type
II receptor. The type I receptor is composed of IL-4 receptor α (IL-4Rα) and the common γ
chain (γc) and initiates Th2 cell differentiation. The type II IL-4 receptor is composed of the
IL-4Rα and IL-13 receptor α1 (IL-13Rα1) subunits. IL-13 shares the type II receptor with
IL-4 and binds an additional receptor, IL-13 receptor α2. In human infants, genetic studies
demonstrate that variations in the IL-4Rα gene are associated with severity of RSV
bronchiolitis [71].
In support of the human data, studies from our laboratory using a neonatal mouse model and
pharmacological knockdown of IL-4Rα reveals that IL-4Rα is required in the pathogenesis
of neonatal RSV infection [50]. Our data clearly indicate that reduction of IL-4Rα in the
lung at the time of initial infection inhibits the development of Th2 cell subsets following
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primary and secondary RSV infection. The reasons for this are just being realized and are
dependent on the use of neonatal models.
In neonatal mice, IL-4Rα [Cormier SA, Unpublished Data] and IL-13Rα1 [72] expression is
elevated on Th1 cells compared with adult Th1 cells. However, the function of these
receptors on Th1 cells is unlike that of Th2 cells; in particular, data from our laboratory and
from Zaghouani’s group using different models (RSV vs ovalbumin, respectively)
demonstrate that IL-4/IL-13 induced by RSV infection or ovalbumin treatment in the
neonate results in the specific depletion of Th1 cells [72,73] [Cormier SA, Unpublished
Data]. Our data further suggest that downregulating IL-4Rα allows for the survival of Th1
cells in the presence of Th2 cytokines such as IL-4/IL-13. These findings strengthen the
importance of the age of initial infection of RSV in determining disease outcome and
suggest that immunomodulatory agents administered at the time of vaccination may be the
key to a successful vaccine.
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Figure 1. PubMed manuscripts referencing the use of rodents in studies of respiratory syncytial
virus
Data is displayed as percent of all rodent studies.
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Figure 2. Summary of the immune responses against respiratory syncytial virus
(A) Neonatal mice express elevated levels of IL-4Rα and IL-13Rα1 on Th1 cells. RSV
infection of neonatal mice results in the rapid production (<24 h) of Th2 cytokines, such as
IL-4 and IL-13. Signaling by IL-4/IL-13 through the IL-4Rα and IL-13Rα1 on Th1 cells
results in their specific depletion by apoptosis. The immaturity of neonatal mDC inhibits
their effective production of IL-12 in response to RSV infection and this, in turn, results in
the prolonged elevation of IL-4Rα and IL-13Rα1 levels on Th1 cells [95]. As the neonatal
mouse matures to an adult, IL-4Rα and IL-13Rα1 declines on Th1 cells. Upon reinfection
with RSV as an adult, IL-4/IL-13 no longer produce Th1 cell apoptosis and stimulate RSV-
specific Th2 cells resulting in an immune response that appears to be Th2 biased. (B) Adult
mice express low levels of IL-4Rα and IL-13Rα1 on Th1 cells. RSV infection of adult mice
results in the rapid production of Th2 and Th1 cytokines. Apoptosis of Th1 cells is greatly
minimized by the reduced levels of the receptors on adult Th1 cells owing to development
and to the increase in IL-12 production from the more mature mDC. Consequently, a Th1
and Th2 response develops.
mDC: Myeloid dendritic cells; R: Receptor; RSV: Respiratory syncytial virus.
Cormier et al. Page 14

























Cormier et al. Page 15
Table 1
Age-specific characteristics of the immune response to respiratory syncytial virus.
Immune responses Adult mice Neonatal mice Human infants
Cellular




CD4+ T cells ++: Th1>Th2 [77] +: Th2>Th1 [50] ++: Th2>Th1 [78,79]
CD8+ T cells +++ [80] +: less IFN-γ producing [80] +++ [81,82]
Dendritic cells Both subsets increase after
infection [83]
mDCs stay the same; pDCs
decrease after infection [Cormier
SA, Unpublished Data]
Both increase in nasal
wash [84]
Alveolar macrophages +++ [49] +++ [49] Increase in the lung
parenchyma and
alveolar spaces [15]
Neutrophils + [49] + [49] +++ [85]
Eosinophils +/− [49] + [49] +/− [85]
Natural killer cells +++ [86] ? +/− [78]
Cytokines
Proinflammatory cytokines IL-1β ++ [87] ? ++ [88]
IL-6 + [15,87,89] ++ [Cormier SA, Unpublished
Data]
++ [87,90,91]
TNF-α + [15,89] + [Cormier SA, Unpublished
Data]
++ [90,91]
Immunoregulatory cytokines IFN-γ +++ [49] +/− [49] − [92]
IFN-α/β +++ [93] IFN-α; +/− IFN-β [Cormier SA,
Unpublished Data]
IL-9 ++ [80] +++ [80] + [90]
IL-4 + [80] + [50] + [94]
IL-12 (p40) ++[87] +++ [50]
IL-12 (p70) + [87] +
IL-13 + [49] ++ [49] +/− [94]




CCL5 +++ [80] + [80] +++ [90]
−: Not detected; +/−: Very little; +: Low; ++: Medium; +++: High; ?: Unknown.
CCL: C–C motif chemokine ligand; DC: Dendritic cell; mDC: Myeloid dendritic cell; pDC: Plasmacytoid dendritic cell.
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